| Document |
Document Title |
|
JP4682377B2 |
An obj ect of the present invention is to provide an inexpensive and simple extraction method for a sialic acid-containing compound from a raw material which is easily available and has no risk of contamination with pathogens affecting a...
|
|
JP2011087589A |
To provide glycoconjugates, therapeutic compositions containing the glycoconjugates, and therapeutic methods of using the glycoconjugates.Peptide constituents of aglyco 10B are provided which are immunogenic epitopes responsible for reco...
|
|
JP2011084516A |
To provide a protein having human-derived glycosaminoglycan decomposition activity with no fear of mixing of a protease and the like as a drug or the like instead of chondroitinase produced by microorganisms; and a method for producing a...
|
|
JP4679055B2 |
Glucoside and glucuronide derivatives of hydromorphone, dihydromorphine, and dihydroisomorphine and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising a glucoside or glucuronide derivative of hydromorphone,...
|
|
JP2011042672A |
To provide a method for extracting and producing aloin from aloe sap or a derivative thereof.The method for producing aloin comprises: extracting aloin from aloe-containing matter, particularly yellow sap of aloe or a derivative thereof,...
|
|
JP4637976B2 |
|
|
JP2011032180A |
To provide a compound that has a high affinity to a CD22 molecule in a B cell and enhances immunoresponse to thereby exhibit activities including an activity of enhancing proliferation of the B cell and an activity of increasing resistan...
|
|
JP4632545B2 |
A compound of the formula (I): and a compound of the formula (V): as well as a compound of the formula (X): which are each a novel siastatin B derivative having a potent inhibitory activity against a glycosidase, are now synthesized by n...
|
|
JP4606048B2 |
|
|
JP4551993B2 |
To provide a cyathane derivative (named as erinacineJ) and an antibacterial agent containing the derivative as an active component, especially an antibacterial agent effective against MRSA (methicillin resistant Staphylococcus aureus). T...
|
|
JPWO2009008362A1 |
The present invention efficiently obtains a sialic acid compound-containing composition having a significantly high sialic acid compound content from milk, whey (milk clear), processed products thereof, etc., which are natural raw materi...
|
|
JP2010529181A |
The invention relates to a process for preparing furanose derivatives, to furanose intermediates used in said process and to the use of said derivatives in the manufacture of atorvastatin.
|
|
JP2010163381A |
To provide a composition that discharges toxins accumulated in the body more simply and effectively than a conventional one and is safe even if taken in a large amount. The detox composition contains uronic acid as an active ingredient a...
|
|
JP4511927B2 |
Thienyl-glycoside compounds (I) are new. Thienyl-glycoside compounds of formula (I) and their salts are new. [Image] R 1, R 2H, halo, OH, NO 2, CN, COOH, COT', COOT', CONH 2, CONHT', CONT' 2, T', 2-6C alkenyl, 2-6C alkynyl, OT', -T'-OH, ...
|
|
JP2009538339T5 |
|
|
JP4496174B2 |
|
|
JPWO2008099560A1 |
To provide a simple production method capable of efficiently producing 5-deoxy-L-arabinose. The production method of the present invention includes a step of hydrolyzing a compound represented by the formula (5) to obtain an aldose deriv...
|
|
JP2010111629A |
To provide a new spiro type antitumor antibiotic produced by a microorganism, the analogs of the same material and a method for obtaining the same.The new spiro type antitumor antibiotic to begin with spiroleptosphol expressed by chemica...
|
|
JP4465164B2 |
|
|
JP4464272B2 |
The object of the present invention is to provide a nucleoside or nucleotide having an unnatural base. The nucleoside or nucleotide of the present invention has a 5-substituted-2-oxo(1H)-pyridin-3-yl group as a base. Preferably, the 5-po...
|
|
JPWO2008090631A1 |
Eliminates problems related to fucoidan absorbability, antigenicity, uniformity, anticoagulant activity, etc. that occur when developing fucoidan, which is a sulfated polysaccharide with an extremely large molecular weight, as a pharmace...
|
|
JP2010083878A |
To provide an excellent cholesterol-reducing agent, and a therapeutic, preventive, or progress-preventive medicine for lipid metabolism disorders, hyperlipemia, and atherosclerosis.The excellent cholesterol-reducing agent includes a comp...
|
|
JP4450456B2 |
Sebum production inhibitors containing as an active ingredient a compound of general formula (1) below having a glucuronic acid derivative and a glucosamine derivative in the structure or a pharmacologically acceptable salt thereof.
|
|
JP2010077044A |
To provide a high-safety composition having an excellent cytoprotection effect on gastric epithelial cell.The agent for gastric epithelial cell cytoprotection includes an acidic xylooligosaccharide containing a glucuronic acid group as a...
|
|
JP2010508371A |
Glucopyranosyl-substituted benzyl-benzonitrile derivatives of general formula (I) as defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to...
|
|
JP2010507667A |
The present invention provides novel isolated compounds characterized as metabolites or derivatives of desmethylvenlafaxine including hydroxy-DV metabolites, hydroxy-DV-glucuronide metabolites, N-oxide-DV metabolites, and benzyl-hydroxy-...
|
|
JP4410913B2 |
The present invention is a compound of general formula (I) or a pharmaceutically acceptable salt of,wherein W represents carbon chain from 9 to 17 which containing double bond or hydroxy group occasionally; X represents carbon chain from...
|
|
JP4401659B2 |
|
|
JP4374426B2 |
The invention relates to substituted benzo(b)thiepine-1,1-dioxide derivatives and to the acid addition salts thereof. The invention relates to compounds of formula (I), wherein R1, R2, R3, R4, R5 and Z have the cited descriptions, to the...
|
|
JP4373917B2 |
The invention relates to a method of analysing heparins or low-molecular-weight heparins. The inventive method is characterised in that the sample to be dosed is depolymerised by heparinases and, if necessary, the depolymerisate obtained...
|
|
JP4365554B2 |
SGLT2 inhibiting compounds are provided having the formulawhereR1, R2, and R2a are independently hydrogen, OH, OR5, lower alkyl, CF3, OCHF2, OCF3, SR5i or halogen, or two of R1, R2 and R2a together with the carbons to which they are atta...
|
|
JP4351629B2 |
The invention provides a compound of formula (I) and pharmaceutically acceptable salts thereof. Processes for the isolating of this bafilomycin metabolite from a novel Micromonospora species, pharmaceutical compositions containing this m...
|
|
JP4346713B2 |
|
|
JP4340042B2 |
|
|
JP2009203162A |
To provide a more efficient and higher yielding method for producing a macrolide compound useful as a medicine that permits stable supply thereof while reducing cost.A macrolide compound (for example, tacrolimus) as a raw material is sub...
|
|
JP2009203230A |
To provide a pharmaceutical composition containing a compound having low adverse effects and exhibiting excellent human SGLT inhibiting activity as an active component and useful for the treatment or prevention of hyperglycemia, glucose ...
|
|
JP2009530311A |
The present invention relates to fluorine-containing monosaccharides that are useful for forming extracellular fluorinated glycoconjugates. Methods of forming extracellular fluorinated glycoconjugates comprise the steps of contacting a c...
|
|
JP4309769B2 |
A novel glucopyranoside, 6-hydroxy-2-p-hydroxybenzylbenzofuran-7-C-beta-D-glucopyrano
side of the formula (1) isolated from Pterocarpus marsupium and to a process for the isolation thereof is disclosed. The invention also relates to a ph...
|
|
JP4302186B2 |
A product obtained by heating at least one substance selected from the following (a), (b) and (c). (a) uronic acid or uronic acid derivative; (b) a saccharide compound containing uronic acid or a saccharide compound containing uronic aci...
|
|
JP4301602B2 |
|
|
JP2009143832A |
To provide an epidermal keratinization normalizing agent which activates epidermal keratinizing cells, has an action to promote the expression of involucrin and keratin 10 of the constituting proteins of cornified envelope, and excels in...
|
|
JP4281976B2 |
The invention concerns compounds of the general formula (I) in which the residues R1 to R7 have the meanings given in the application as well as methods for their preparation. The compounds are in particular suitable as substrates for RN...
|
|
JP4273116B2 |
The present invention provides a therapeutic agent for nerve damages such as those caused by spinal cord injury or nerve trauma, which comprises, as an active ingredient, a low-molecular-weight saccharide composed of at least glucuronic ...
|
|
JP4262480B2 |
Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in prepari...
|
|
JP2009096729A |
To provide a composition having high safety and excellent regulating actions on immunological functions.The composition having regulating actions on immunological functions comprises an acidic xylooligosaccharide that has an average poly...
|
|
JP4255138B2 |
The present invention discloses the use, in the manufacture of a preventive and therapeutic drug of a brain disease, of a compound represented by formula (1): CH2=CH-CH2-S(O)n-R Äwherein R represents a hydrogen atom, an alkyl group, an ...
|
|
JP2009073806A |
To provide an IGF-1 secretagogue without problems such as skin irritation and effective such as for: inhibition of skin crease by increased skin elasticity; amelioration of skin sag; and hair growth.The insulin-like growth factor-1 secre...
|
|
JP2009073845A |
To provide a composition and method for identifying a molecule of a potent inhibitor on axon regeneration in myelin, and blocking or operating a MAG active level in the neural system to treat a patient having injuries to a neural system ...
|
|
JP4247775B2 |
C-glycoside compounds are suited for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and/or proteoglycans, advantageously proteoglycans con...
|
|
JP2009057387A |
To provide a method for producing an anti-inflammatory agent exhibiting high pharmacological activity, no side effect, and high safety by using natural products as raw materials.The method for producing an anti-inflammatory agent for ext...
|
